Metabolic & Endocrine · Clinical trials
Type 1 Diabetes Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About type 1 diabetes — and why its trials are hard
Type 1 diabetes (T1D) is a chronic autoimmune disease in which T-cell-mediated destruction of pancreatic beta cells causes absolute insulin deficiency, requiring lifelong exogenous insulin. For a century, therapy has been replacement-based, evolving from animal-derived insulin to recombinant human insulin and engineered analogues (glargine, detemir, degludec, lispro, aspart) that better mimic basal-bolus physiology and reduce hypoglycemia. The modern frontier is disease modification: preserving or preventing loss of beta-cell function. In 2022 teplizumab (Tzield), an anti-CD3 monoclonal antibody, became the first drug shown to delay progression from Stage 2 to clinical Stage 3 T1D, validating immunomodulation in at-risk, autoantibody-positive individuals. This landmark followed decades of immunotherapy failures, including otelixizumab and the DEFEND program, which repeatedly missed C-peptide preservation endpoints. Adjunctive agents (pramlintide; SGLT inhibitors in some regions) and automated insulin-delivery systems further refine glycemic control. Research now targets earlier intervention, combination immunotherapy, and beta-cell replacement to alter the disease trajectory rather than only replace insulin.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Teplizumab (Tzield) | 2022 | Delay of onset of Stage 3 T1D in Stage 2 (autoantibody-positive, dysglycemic) patients aged 8+ | TN-10 (At-Risk) Phase 2, TrialNet, published NEJM 2019 | Time from randomization to clinical (Stage 3) T1D diagnosis | Median delay of onset ~24 months (17.0 vs 43.5 months in extended follow-up); reduced hazard of progression versus placebo |
| Insulin degludec (Tresiba) | 2015 | Long-acting basal insulin for T1D and T2D | BEGIN program; DEVOTE (CV safety) | HbA1c reduction; nocturnal/overall hypoglycemia rates | Non-inferior HbA1c with significantly lower rates of nocturnal hypoglycemia versus glargine U100 |
| Insulin glargine (Lantus) | 2000 | Long-acting basal insulin analogue | Multiple registration trials versus NPH insulin | HbA1c control and hypoglycemia | Comparable HbA1c with reduced nocturnal hypoglycemia and flatter 24-hour profile versus NPH |
| Insulin aspart (NovoLog / Fiasp) | 2000 | Rapid-acting mealtime (prandial) insulin analogue | Registration trials versus regular human insulin | Postprandial glucose excursion; HbA1c | Faster onset improved postprandial glucose control versus regular human insulin |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in type 1 diabetes development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Otelixizumab (anti-CD3) — DEFEND-1 / DEFEND-2 (new-onset T1D) | Failed to preserve C-peptide; did not meet primary endpoint of change in stimulated C-peptide | Lower cumulative dosing (chosen to limit reactivation of Epstein-Barr virus and cytokine effects) is widely cited as blunting efficacy |
| Rituximab / abatacept / other immunotherapies — TrialNet new-onset studies | Transient but ultimately non-durable slowing of C-peptide decline; no lasting disease modification | Single-agent immune modulation insufficient to halt ongoing autoimmunity; effect waned after treatment |
| Oral insulin (antigen-specific prevention) — TrialNet Oral Insulin Prevention Study | Did not delay onset of T1D overall in the primary autoantibody-positive population | Mucosal tolerance strategy showed at most subgroup signals; overall endpoint not met |
Choosing the right endpoint
Primary endpoints that matter in type 1 diabetes trials
- Stimulated C-peptide (AUC/2-hour mixed-meal) — Gold-standard biomarker of residual endogenous beta-cell function in intervention trials
- Time to Stage 3 (clinical) T1D — Prevention/delay endpoint used in at-risk populations, as in the teplizumab TN-10 study
- HbA1c — Integrated ~3-month glycemic control measure for insulin and adjunctive therapy trials
- Hypoglycemia rate (nocturnal and severe) — Key safety/tolerability endpoint distinguishing modern basal analogues
How iNGENū runs type 1 diabetes trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Type 1 Diabetes clinical trials — FAQs
Does teplizumab cure or prevent type 1 diabetes?
Why have so many T1D immunotherapies failed?
What is the mainstay of treatment?
Ready to discuss your type 1 diabetes trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal